ArticleFrontiers in microbiology2018
Efficacy of Colistin and Its Combination With Rifampin
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Recurrent mycotic aortic aneurysm withJournal of vascular surgery cases and innovative techniques · 2026Article
- The synergistic effect of the combination of polymyxin B and rifampicin in a murine neutropenic thigh infection model with E. coli and K. pneumoniae.The Journal of antimicrobial chemotherapy · 2025Article
- In Vitro Synergistic Activity of Rifampicin Combined with Minimal Effective Antibiotic Concentration (MEAC) of Polymyxin B Against Extensively Drug-Resistant, Carbapenem-, and Polymyxin B-Resistant Klebsiella pneumoniae Clinical Isolates.Current microbiology · 2024Article
- Efficacy of Tamoxifen Metabolites in Combination with Colistin and Tigecycline in Experimental Murine Models ofAntibiotics (Basel, Switzerland) · 2024Article
- Novel evidence on sepsis-inducing pathogens: from laboratory to bedside.Frontiers in microbiology · 2023Review
- IgM-enriched immunoglobulin improves colistin efficacy in a pneumonia model byLife science alliance · 2022Article
- Carbapenem Combinations for Infections Caused by Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2022Article
- Efficacy of dual carbapenem treatment in a murine sepsis model of infection due to carbapenemase-producing Acinetobacter baumannii.The Journal of antimicrobial chemotherapy · 2021Article
- Efficacy of Fosfomycin and Its Combination With Aminoglycosides in an Experimental Sepsis Model by Carbapenemase-ProducingFrontiers in medicine · 2021Article
- In Vitro Activity of Pentamidine Alone and in Combination with Antibiotics against Multidrug-Resistant ClinicalAntibiotics (Basel, Switzerland) · 2020Article
- Article
- Synergistic Activity of Niclosamide in Combination With Colistin Against Colistin-Susceptible and Colistin-ResistantFrontiers in cellular and infection microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the relevance of carbapenemase-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.